Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study

• Published in: Clinical & Translational Immunology 2020, Vol.9 (10), p.e1192-n/a
• Main Authors: Shao, Ziyun, Feng, Yongwen, Zhong, Li, Xie, Qifeng, Lei, Ming, Liu, Zheying, Wang, Conglin, Ji, Jingjing, Liu, Huiheng, Gu, Zhengtao, Hu, Zhongwei, Su, Lei, Wu, Ming, Liu, Zhifeng
• Format: Article
• Language: English
• Subjects: Age; Blood pressure; Cardiovascular disease; clinical efficacy; Cohort analysis; Comorbidity; Coronaviruses; COVID-19; Demographics; Diabetes; Dosage; Hypertension; Immunoglobulins; Infections; Inflammation; Intravenous administration; IVIG; Laboratories; Lymphocytes; Medical prognosis; Medical research; Mortality; Original; Patients; Physiology; Proteins; SARS‐CoV‐2; Severe acute respiratory syndrome coronavirus 2; Viral infections
• ISSN: 2050-0068; 2050-0068
• DOI: 10.1002/cti2.1192

Objective Coronavirus disease 2019 (COVID‐19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID‐19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID‐19 patients was lacking. Methods 325 patients with laboratory‐confirmed critical COVID‐19 were enrolled from 4 government‐designated COVID‐19 treatment centres in southern China from December 2019 to March 2020. The primary outcomes were 28‐ and 60‐day mortality, and the secondary outcomes were the total length of in‐hospital and the total duration of the disease. Subgroup analysis was carried out according to clinical classification of COVID‐19, IVIG dosage and timing. Results In the enrolled 325 patients, 174 cases used IVIG and 151 cases did not. The 28‐day mortality was improved with IVIG after adjusting confounding in overall cohort (P = 0.0014), and the in‐hospital and the total duration of disease were longer in the IVIG group (P